Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo Moves From Health Care To 'Self Care'

Executive Summary

Providing self-care products "opens this organization up to massive opportunity" which Perrigo will identify in early 2019, says new CEO Murray Kessler. It remains committed to selling or spinning off its Rx unit, though it's "just a few FDA approvals away from significantly" growing, he says as firm reports $68m net loss in its latest quarter.

Advertisement

Related Content

Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount
Another Change At Perrigo Helm As Results Remain Turbulent
Perrigo Looks To Spin Out Or Sell Off Rx Business, But Will Separating Generics Add Value?
Perrigo's OTC Core Could Expand To Include National Brands
Perrigo Generic Of Teva's ProAir Stunned By Another FDA CRL
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124223

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel